Alzheimer's disease: common worries in old age

Estimated reading time: 8 minutes

Alzheimer is a progressive neurological disorder that primarily affects memory, thinking, and behavior. It is the most common cause of dementia, accounting for 60-80% of cases worldwide. Despite extensive research, Alzheimer's remains a complex disease with no known cure. However, understanding its causes, recognizing symptoms early, and adopting management strategies can significantly improve the quality of life for those affected.

---

What Causes Alzheimer’s Disease?

The exact causes of Alzheimer’s disease are not fully understood, but research points to a combination of genetic, environmental, and lifestyle factors. Two main pathological hallmarks are linked to the disease:

Amyloid Hypothesis: the accumulation of beta-amyloid plaques is considered a central pathogenic event. Genetic mutations in the amyloid precursor protein (APP) and presenilin genes contribute to familial AD by increasing beta-amyloid production (Blennow et al., 2006).

Tau Protein Dysregulation: hyperphosphorylated tau proteins form neurofibrillary tangles, disrupting neuron function and contributing to neurodegeneration (Weller & Budson, 2018).

Genetic Factors: familial AD is linked to mutations in genes like APP, PSEN1, and PSEN2. The ε4 allele of the apolipoprotein E (APOE) gene increases risk for late-onset AD (Bird, 2008).

Age and Environmental Risks: aging and environmental factors such as head injuries, vascular disease, and exposure to certain metals like aluminum and copper may increase susceptibility (Armstrong, 2013).

Mitochondrial and Metabolic Dysfunctions: impaired mitochondrial function and disrupted calcium homeostasis are associated with neuronal death in AD (Hölscher, 1998).

Inflammation and Immune Response: chronic inflammation and immune dysregulation may exacerbate AD progression (Fan et al., 2020).

These changes lead to the death of brain cells, shrinking of brain tissue, and ultimately, the loss of cognitive and functional abilities.

---

Symptoms of Alzheimer’s Disease

Alzheimer’s symptoms typically develop gradually and worsen over time. They are categorized into three stages: early, middle, and late stage (Alzheimer's Association)

Early Stage Symptoms

• Forgetfulness, particularly of recent events.
• Difficulty concentrating or making decisions.
• Losing track of time or place.
• Misplacing items frequently.

Middle Stage Symptoms

• Increasing memory loss, including inability to recognize family or friends.
• Difficulty performing everyday tasks, such as cooking or managing finances.
• Changes in personality, such as irritability, anxiety, or depression.
• Wandering and confusion about location or time.

Late Stage Symptoms

• Severe memory impairment and inability to communicate.
• Loss of mobility and control over bodily functions.
• Dependence on others for daily care.

---

Risk Factors for Alzheimer’s Disease

Several factors increase the likelihood of developing Alzheimer’s (Richard A Armstrong, 2019):

Genetic Risk Factors:

• Mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are linked to early-onset AD.
• The apolipoprotein E (APOE) ε4 allele increases the risk of late-onset AD.

Age and Gender:

• Advancing age is the strongest risk factor. Women are at higher risk than men due to longevity and possible hormonal influences.

Vascular and Metabolic Factors:

• Hypertension, diabetes, midlife obesity, and smoking are linked to an increased risk of AD. These factors may impair brain vascular health. 

Lifestyle Factors:

• Physical inactivity, low educational attainment, and social isolation increase risk. Cognitive activity and lifelong learning reduce risk.

Head Injury:

• Traumatic brain injury (TBI) in earlier life is associated with a heightened risk of dementia.

Psychological Factors:

• Depression and chronic stress are associated with an increased risk of AD. These may reflect prodromal phases or causal factors.

Environmental and Occupational Exposures:

• Exposure to certain pesticides, metals (like aluminum), or fumigants might contribute, although evidence is less definitive.

Protective Factors:

• Regular physical exercise, moderate alcohol consumption, adherence to a Mediterranean diet, and social engagement are protective against AD.

---

Diagnosis

Diagnosing Alzheimer’s Disease (AD) involves clinical evaluations, imaging, biomarkers, and exclusion of other conditions (Alzheimer's Association):

• Clinical Criteria:
  AD is characterized by a gradual onset and progressive cognitive decline, particularly in memory. Diagnosis often involves clinical assessments to identify cognitive impairments while excluding other possible causes.
• Neuropsychological Tests:
  Tools like the Mini-Mental State Examination (MMSE) and others are used to assess memory, reasoning, and language. These provide objective evidence of dementia.
• Biomarkers:
  Biomarkers in cerebrospinal fluid (CSF), such as beta-amyloid and tau proteins, as well as amyloid PET imaging, aid in early detection and differential diagnosis. They help confirm the presence of AD pathology.
• Neuroimaging:
  Structural imaging (MRI or CT) identifies brain atrophy, particularly in the hippocampus. Functional imaging (FDG-PET or SPECT) shows reduced metabolic activity in affected brain regions.

• Differential Diagnosis:
  AD is distinguished from other dementias, such as vascular dementia or Lewy body dementia, by its characteristic progressive memory loss and lack of early motor or coordination deficits.
• Challenges in Early Diagnosis:
  Preclinical AD and mild cognitive impairment (MCI) stages are difficult to diagnose due to overlapping symptoms with normal aging. Staging frameworks and advanced biomarkers are being developed to address these challenges.
• Ocular and Retinal Markers:
  Non-invasive retinal imaging is emerging as a promising tool for detecting AD-related changes, offering potential for earlier diagnosis.

---

Treatment and Management

While there is no cure for Alzheimer’s disease, several approaches help manage symptoms and improve quality of life:

Medications for Alzheimer’s Disease (AD)

1. Cholinesterase Inhibitors:
   • Examples: Donepezil, Rivastigmine, Galantamine.
   • Mechanism: These medications inhibit the enzyme acetylcholinesterase, which breaks down acetylcholine, a neurotransmitter crucial for memory and learning. By increasing acetylcholine levels, these drugs improve communication between nerve cells.
   • Indication: Most effective in managing symptoms of mild to moderate AD.
   • Benefits: Can temporarily improve cognitive function and manage behavioral symptoms such as agitation or depression.
   • Side Effects: Common side effects include nausea, vomiting, diarrhea, loss of appetite, and in some cases, muscle cramps or insomnia.
2. Memantine:
   • Mechanism: Works by regulating the activity of glutamate, another neurotransmitter involved in memory and learning. Memantine protects nerve cells from excessive stimulation by glutamate, which can lead to cell damage (excitotoxicity).
   • Indication: Typically prescribed for moderate to severe AD, either alone or in combination with cholinesterase inhibitors.
   • Benefits: May slow cognitive decline and help maintain daily functioning.
   • Side Effects: Generally well tolerated but may include dizziness, confusion, headache, or constipation.

Combination Therapy

• In some cases, cholinesterase inhibitors and memantine are used together to target multiple pathways associated with cognitive decline. This approach may provide more comprehensive symptom management.

Emerging and Supportive Therapies

• Antipsychotics: Sometimes used off-label for managing severe behavioral symptoms but require careful monitoring due to side effects.
• Antidepressants and Anxiolytics: Help manage mood disorders and anxiety, which are common in AD.
• Lifestyle and Cognitive Interventions: Combined with medication, these can improve quality of life and potentially enhance the benefits of pharmacological treatments.

Lifestyle Interventions

• Healthy Diet: A Mediterranean diet rich in fruits, vegetables, whole grains, and fish may support brain health.
• Regular Exercise: Physical activity improves blood flow and reduces cognitive decline.
• Cognitive Stimulation: Engaging in puzzles, reading, or social activities helps maintain mental sharpness.

Supportive Care

• Family members and caregivers play a crucial role in ensuring the well-being of individuals with Alzheimer’s. Joining support groups or seeking professional counseling can help caregivers manage stress and responsibilities.

---

Prevention Strategies

Although Alzheimer’s cannot be fully prevented, these steps may reduce the risk:

1. Stay Mentally Active: Lifelong learning and challenging your brain with new skills.
2. Maintain a Healthy Heart: Controlling blood pressure, cholesterol, and blood sugar levels.
3. Adopt a Balanced Lifestyle: Regular physical activity, nutritious diet, and sufficient sleep.
4. Avoid Smoking and Limit Alcohol: Both contribute to brain degeneration.

---

The Future of Alzheimer’s Research

Scientists are exploring various avenues to combat Alzheimer’s. Promising research areas include:

• Immunotherapy: Developing antibodies to target amyloid and tau proteins.
• Gene Therapy: Investigating genetic modifications to prevent or slow disease progression.
• Early Detection: Refining diagnostic tools to identify Alzheimer’s before symptoms appear.

---

Conclusion

Alzheimer’s disease is a challenging condition, not just for those diagnosed but also for their loved ones and caregivers. Early detection and proactive management can help slow the disease's progression and improve the quality of life. Continued research and awareness are essential to uncover effective treatments and, ultimately, a cure. Until then, a supportive and compassionate approach remains the cornerstone of care for those affected by Alzheimer’s disease.

Naturem™ Memory+ – Unlock Your Cognitive Potential

Naturem™ Memory+ is a premium dietary supplement designed to help enhance cognitive function, improve memory, and support optimal brain health. Formulated with powerful natural ingredients, it helps promote neuron regeneration, boost antioxidant activity, strengthen immunity, and maintain a healthy brain-gut balance.

Key Ingredients & Benefits:

• Ginkgo Biloba – Traditionally used to enhance memory and cognitive speed.
• Bacopa Monnieri – Supports memory retention and reduces anxiety.
• Phosphatidylserine – Essential for maintaining healthy brain cell membranes.
• Acetyl-L-Carnitine – Fuels brain cells by supporting energy production.
• Vitamin B12 – Vital for nerve health and cognitive function.

Naturem™ Memory+ is ideal for those looking to improve concentration, boost cerebral circulation, and support long-term brain health. It may also aid in managing Alzheimer’s symptoms.

Usage: Take daily as directed on the product label.

Elevate your cognitive performance naturally with Naturem™ Memory+! Read more

References

Blennow, K., de Leon, M. J., & Zetterberg, H. (2006). Alzheimer's disease. The Lancet, 368(9533), 387–403. DOI: 10.1016/S0140-6736(06)69113-7

Weller, J., & Budson, A. (2018). Current understanding of Alzheimer’s disease diagnosis and treatment. The American Journal of Medicine, 131(10), 1161–1167. DOI: 10.1016/j.amjmed.2018.01.022

Bird, T. D. (2008). Genetic aspects of Alzheimer’s disease. Genetics in Medicine, 10(4), 231–239. DOI: 10.1097/GIM.0b013e31816b64dc

Armstrong, R. A. (2013). What causes Alzheimer’s disease? Folia Neuropathologica, 51(3), 169–188. DOI: 10.1016/j.exger.2013.04.011

Hölscher, C. (1998). Possible causes of Alzheimer’s disease: Amyloid fragments, free radicals, and calcium homeostasis. Neurobiology of Aging, 19(2), 91–93. DOI: 10.1016/S0197-4580(98)00009-5

Alzheimer's Association - Stages of Alzheimer's.  https://www.alz.org/alzheimers-dementia/stages

Alzheimer's Association - Medical Tests for Diagnosing Alzheimer's. https://www.alz.org/alzheimers-dementia/diagnosis/medical_tests

Richard A Armstrong (2019). Risk factors for Alzheimer's disease. Folia Neuropathol. 2019;57(2):87-105. DOI: 10.5114/fn.2019.85929.